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Abstract
Viral variants with decreased susceptibility to HCV protease inhibitors (PIs) occur naturally and preexist at low levels within
HCV populations. In patients failing PI monotherapy, single and double mutants conferring intermediate to high-level
resistance to PIs have been selected in vivo. The abundance, temporal dynamics and linkage of naturally occurring
resistance-associated variants (RAVs), however, have not been characterized in detail. Here, using high-density
pyrosequencing, we analyzed HCV NS3 gene segments from 20 subjects with chronic HCV infection, including 12 subjects
before and after liver transplantation. Bioinformatics analysis revealed that Q80 substitution was a dominant variant in 40%
of the subjects, whereas other RAVs circulate at low levels within quasispecies populations. Low frequency mutation linkage
was detectable by Illumina paired-end sequencing in as low as 0.5% of the mock populations constructed from in vitro RNA
transcripts but were uncommon in vivo. We show that naturally occurring RAVs are common and can persist long term
following liver transplant at low levels not readily detectable by conventional sequencing. Our results indicate that mutation
linkage at low levels could be identified using the Illumina paired-end approach. The methods described here should
facilitate the analysis of low frequency HCV drug resistance, mutation linkage and evolution, which may inform future
therapeutic strategies in patients undergoing direct acting antiviral therapies.
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Introduction
Hepatitis C virus (HCV) infects over 180 million individuals
worldwide and is the leading cause of liver transplantation due to
cirrhosis and hepatocellular carcinoma [1]. Historically, interfer-
on-based regimen with ribavirin is the gold standard for the
treatment of chronic HCV infection, but the rate of sustained
virologic response (SVR) has been suboptimal. Remarkably, the
addition of NS3/4A protease inhibitor to peginterferon-ribavirin
improves the SVR rate substantially in both treatment naı̈ve and
treatment experienced individuals [2–9]. With a pipeline of direct
acting agents (DAAs) in development, there is tremendous
enthusiasm for HCV therapeutics. While data for new protease
inhibitors are encouraging, resistance to this and other classes of
drugs may become an important consideration, especially in
anticipation of interferon-free regimens in the coming years.
Resistance-associated variants (RAVs) to NS3/4A protease
inhibitors have been identified in both in vitro studies and clinical
trials [10,11]. In treatment-naı̈ve patients, naturally occurring
dominant RAVs are common [12]. The quasispecies nature of
HCV raises the concern that viral swarms may harbor preexisting
mutations at low frequency not readily detectable by conventional
genotyping methods, which may influence treatment outcome.
Indeed, mathematical modeling of HCV replication suggests that
RAVs preexist, which can emerge rapidly under selective drug
pressure [13,14]. The presence of preexisting RAVs is further
supported by the observation that RAVs are selected rapidly in
subjects receiving protease inhibitor monotherapy [10,11], typi-
cally within days of initiating DAAs. Importantly, lessons from the
HIV field indicate that preexisting drug resistant variants at low
frequencies could contribute to treatment failure [15], and thus
genotypic resistance testing is now the standard of care prior to
initiating antiretroviral therapy. For HCV, the prevalence of
dominant, naturally occurring RAVs has been previously reported
[12,16–18]. However, the abundance, mutation linkage and
evolution of RAVs that circulate at low frequencies have not
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been characterized in depth in patients undergoing liver trans-
plantation. A detailed examination of resistance profiles is
important for identifying clinically relevant drug resistance
variants and optimizing strategy to improve treatment outcome.
Studies of low frequency HCV variants have long been
hampered by the lack of sensitive sequencing methods. New
sequencing technologies, such as Roche/454 pyrosequencing and
Illumina sequencing, have made it possible to deeply sequence a
larger number of samples simultaneously. The use of these
technologies has led to sensitive detection of low abundance
mutations in HIV and HBV quasispecies [19,20], and the analysis
of HCV viral dynamics and transmission bottlenecks [21]. Here,
we present the results of sequencing barcoded PCR amplicons to
quantify variants associated with NS3 resistance from 20 subjects
with chronic HCV infection, including longitudinal samples from
12 liver transplant recipients. We show that naturally occurring,
low frequency RAVs are common in chronic HCV, and can
persist long term following liver transplantation. We also addressed
the question of whether linkage between mutations far apart on
the same HCV genome could be quantified using a modified
Illumina paired-end sequencing approach. We used mock in vitro
transcribed RNA communities to show that the paired-end
approach could identify linked variants at two ends of long
amplicons. Although linkage of pre-existing mutational variants
was uncommon in our treatment-naı̈ve cohort, the paired-end
approach should be useful during direct antiviral therapy and
generally applicable to linkage analysis in other genomic loci of
HCV or other viruses. The methods described here should
facilitate longitudinal analyses of RAVs in vivo and provide a
framework for future studies on the impact of preexisting RAVs on
treatment outcome using DAAs.
Methods
Ethics statement
Serum samples before and after liver transplantation were
collected at the University of North Carolina Liver Center under a
University of North Carolina at Chapel Hill Institutional Review
Board-approved protocol with written informed consent from all
participants. Archived clinical samples for chronic HCV were
obtained at University of Florida under a University of Florida
Institutional Review Board protocol approved for a waiver for
Informed Consent in accordance with 45 CFR 46.116(d) under
research category #5 for research involving materials (data,
documents, records, or specimens) that have been collected, or will
be collected solely for nonresearch purposes (such as medical
treatment or diagnosis). All samples were from subjects who were
protease inhibitor treatment naı̈ve.
Figure 1. Deep sequencing strategy to determine abundance and mutation linkage of NS3 RAVs. (A) Roche/454 pyrosequencing. Primer
binding sites for 454/Roche pyrosequencing primers are shown in yellow. The pyrosequencing primers are composites containing the required
sequences for the Roche/454 titanium chemistry procedure at 59 end (blue and green), a unique 8-base DNA barcode that indexes each sample (red),
and HCV-specific primer sequences at the 39 end (yellow). (B) Illumina paired-end sequencing. Partial NS3 gene segments were first amplified using
gene-specific primers that contain HCV-specific sequences (yellow), a barcode sequence unique to each sample (red) and partial adapter sequences
(green and blue). Amplified fragments were tailed with flow cell adaptors (green and blue arrows), then subjected to paired-end sequencing using
the standard Illumina paired-end protocol. This protocol will generate non-overlapping forward (100 nt) and the reverse (100 nt) reads from each
cluster, providing precise long-range positional and sequence information. After trimming and quality control, the paired-end reads allowed linkage
analysis between V36-V55 and R155-I170. Sequences of all primers used in (A) and (B) are listed in Supporting Information S1.
doi:10.1371/journal.pone.0069698.g001
NS3 Resistance in Liver Transplant
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69698
Amplification of NS3 gene segments
Viral RNA was extracted from plasma, and quantified by
quantitative RT-PCR using primers specific to highly conserved 59
UTR of the HCV genome (Supporting Information S1). For
pyrosequencing, NS3 gene segments of approximately 600 nt
(corresponding to coordinates 3342 to 3951 on the H77 genome,
accession NC_004102) were amplified using HCV-specific primers
that contained the required adaptor sequences for the Roche/454
titanium chemistry procedure and a unique 8-bp barcode that
indexed each sample, which allowed multiplex pyrosequencing.
For Illumina sequencing, the gene-specific primers contained
unique 4 to 8 bp index sequence and Illumina PE adapters
(Figure 1 and Supporting Information S1). Control RNA of known
sequence was generated by in vitro transcription of linearized
plasmid containing a T7 promoter and full-length H77C genotype
1a sequence. The in vitro control transcripts were subjected to
identical experimental procedures including RT-PCR and pyro-
sequencing as patient-derived viral RNA (Supporting Information
S1).
Roche/454 pyrosequencing
RT-PCR amplicons were gel purified, pooled, and subjected to
bidirectional pyrosequencing using the Titanium chemistry on the
Roche/454 GS-FLX platform. Pyrosequence reads were filtered
using the following quality control criteria: (i) an exact match to
barcode and primer sequences, (ii) .360 bases in length for
forward reads; .290 bases for reverse reads, and (iii) no
ambiguous bases (Ns) (Supporting Information S1). Forward and
reverse reads were trimmed to ,337 and ,264 bases, respective-
ly, then aligned to H77C reference sequence using global multiple
sequence alignment. The codons associated with resistance to
protease inhibitors were identified. Of the reads that contained
codon-changing nucleotide substitutions, pairwise sequence align-
ments were performed followed by manual inspection of the
aligned sequences. Technical error rates were determined using in
vitro control transcripts of known NS3 sequences that were
amplified and sequenced in parallel. To distinguish authentic
variants at drug resistance sites from technical artifacts, position-
specific background error rate was calculated to define authentic
drug resistance mutations using a chi-square test at p#0.05. The
forward pyrosequence reads were used to form operational
taxonomic units (OTUs) for subsequent quasispecies diversity
analysis.
Quasispecies diversity analysis
Forward 454 pyrosequence reads (corresponding to coordinates
3342 to 3674 on the H77 genome, accession NC_004102) were
clustered into operational taxonomic units (OTUs) with a 97%
identity threshold (accepting nine differences over 300 nt),
excluding chimeras and sequences represented by singletons and
doubletons. As described previously [21], we chose a 3%
difference to cluster reads into OTUs as a reasonable compromise
for trying to maintain some of the rare authentic variability while
minimizing error-induced variability. For each OTU cluster, reads
were aligned to generate a consensus sequence (,337 bp), which
was used to represent the dominant sequence for each quasispecies
(or OTU) and for phylogenetic analysis. Phylogenetic trees were
constructed using the UPGMA method with either Geneious or
the Phangorn package in R [22]. Shannon index values were
calculated to determine quasispecies diversity (Supporting Infor-
mation S1). All sequence datasets have been deposited in the
NCBI Sequence Read Archive (SRA) under accession
no. SRA059141.
Mutation linkage analysis by Illumina paired-end
sequencing
Because the forward and the reverse 454 reads (following
trimming of barcode and primer sequences) did not overlap to
allow reconstruction of haplotypes for linkage analysis, we applied
the Illumina paired-end technology to determine mutation
linkage. Partial NS3 gene segments (,460 nt) were amplified
using gene-specific primers that contain a barcode sequence
unique to each sample and partial sequences for the adaptor
(Supporting Information S1). Therefore, linkage between paired-
end reads was determined based on the assigned barcodes and the
sequences coordinates in the illumine flowcell. Amplified frag-
ments were gel-purified, pooled at equimolar concentrations, and
tailed with flow cell adaptors (Figure 1). The enriched library was
quantified using Kapa Library Quantification kit (Kapa Biosys-
tems, Woburn, MA) and subjected to standard Illumina paired-
end sequencing at 26100 bp on Illumina Genome Analyzer IIx at
the University of Florida ICBR sequencing core. Paired-end reads
were processed using the following criteria: (i) an exact match to
barcode and primer sequences; (ii) no ambiguous bases; and (iii)
both forward and reverse sequences pass all quality steps (no reads
with unknown ‘B’ quality scores and no reads that failed Illumina
quality check ‘0’). The filtered, trimmed reads were aligned to
H77C reference sequence, and the codons associated with PI
resistance were identified and the mutation frequency calculated.
Results
Patients and samples
We performed direct Sanger population sequencing and
Roche/454 pyrosequencing of partial NS3 gene fragments on 55
serum samples from 20 PI treatment naive subjects with chronic
HCV infection. These included samples from 8 subjects with
chronic HCV infection and 47 longitudinal HCV samples from 12
liver transplant (LT) recipients, in whom up to 5 samples pre- and
post-LT were analyzed (Table 1). We also performed Illumina
paired-end sequencing to assess mutation linkage in selected
samples. All 20 subjects harbored genotype 1 virus (14 GT1a and
6 GT1b), as determined by NS5B gene sequencing [23]. All 12
liver transplant recipients received immunosuppressive regimen
post-LT.
Acquisition and analysis of pyrosequencing data
HCV RNA was amplified using primers complementary to
HCV sequences. Primers were designed based on an alignment of
374 full-length HCV genotype 1 sequences from the Los Alamos
HCV database [24]. All amplicons were sequenced bi-direction-
ally. To minimize re-sampling of low viral load RNA templates, all
samples were quantified by quantitative RT-PCR and a median
2.56105 copies of RNA per reaction were used in the amplifica-
tion step.
After quality control, a total of 336,934 pyrosequence reads
(3,63361,538 reads per sample) were available for analysis. To
distinguish authentic variants at drug resistance sites from
technical artifacts, we subjected in vitro NS3 transcripts from a
cloned H77C plasmid [25] to identical procedures including RT-
PCR and pyrosequencing as patient-derived viral RNA. This
provided a direct measure of technical error rates from RT-PCR
and the sequence determination steps. Consistent with the
published data [20], the overall mean error rate was ,0.5%,
with indels accounting for the majority of the errors (,75% indels,
,25% substitution errors). As reported previously [19], the
mismatch error rate was position-dependent. Thus, we used
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Table 1. Demographics, viral load, and time points of the samples used in this study.





A 41 Male Caucasian 1a N/A 1,192,920 N/A
B 56 Male Hispanic 1a N/A 1,636,980 N/A




D 44 Male Native American 1a 2113 N/D
380 357,000 Tacrolimus
810 2,510,000 Prograf
E 46 Male Caucasian 1a 266 N/D
57 .700,000 Prograf
746 418,000 Prograf
F 54 Male African American 1a 2284 293,000
99 N/D Prograf/Prednisone
1163 .5,000,000 Prograf









I 59 Male Caucasian 1a N/A 433,210 N/A
J 60 Female Caucasian 1a N/A 638,441 N/A




L 45 Male African American 1a N/A 523,391 N/A





N 53 Male Caucasian 1a 2602 369,000
69 1,710,000 Prograf
195 1,670,000 Prograf
O 54 Female Caucasian 1b N/A 2,433,800 N/A
P Unk Unk Unk 1b N/A 2,841,586 N/A
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position-specific background error rates to define authentic drug
resistance mutations.
Naturally occurring NS3/4A RAVs in chronic HCV
NS3/4A inhibitors fall into two structural classes: linear
ketoamides and macrocyclic compounds. Differences in their
chemical scaffold have led to two major drug resistance profiles
[26,27]. For example, V36A/M, T54A/S, and V170A/T confer
resistance to most linear ketoamides, whereas variants at Q80 and
D168 are associated with resistance to macrocyclic compounds.
Substitutions at R155K/T and A156V/T/S confer cross-
resistance between the two classes [26]. To assess the abundance
of RAVs in chronic HCV infection, we used pyrosequencing to
analyze 20 HCV quasispecies including 8 samples from chronic
HCV and 12 pre-LT samples from LT recipients. We queried
eight main amino acid positions known to be associated with NS3/
4A resistance (V36, T54, V55, Q80, R155, A156, D168, and V/
I170) (Figure 2A). We considered drug resistance calls as authentic
if the frequencies determined by pyrosequencing reads were
significantly enriched compared to the background technical error
rates (p,0.05; chi-square). Overall, 31 of the 104 RAVs detected
in our pyrosequence reads (29.8%) were considered authentic
RAVs.
As expected, conventional sequencing detected the most
abundant RAVs (Figure 2, asterisks), while clonal sequencing
detected additional minor variants (Supporting Information S1).
Fourteen of 20 subjects (70%) harbored no dominant RAVs as
determined by population sequencing. No dominant RAVs were
observed at positions 36, 54, 155, 156, 168 and 170, consistent
with observed low prevalence of high-level, naturally occurring PI-
resistant variants reported previously [12,28]. Overall, conven-
tional sequencing failed to identify 77.4% (24 of 31) of authentic
PI-resistant substitutions, most of which were low-frequency
variants. These results demonstrate that naturally occurring RAVs
are common but most RAVs circulate at low frequencies not
readily detectable by conventional sequencing.
Temporal dynamics of HCV quasispecies in liver
transplantation
To examine the evolution of HCV quasispecies, we analyzed 1–
2 samples pre-LT and 2–3 samples post-LT for 12 liver transplant
recipients (9 GT1a and 3 GT1b). Phylogenetic analysis based on
the pyrosequencing reads revealed that temporally associated
intra-host HCV quasispecies populations were more closely
related to one another than HCV populations between subjects
(Figure 2B). To investigate intra-host HCV evolution, we clustered
all pyrosequence reads into operational taxonomic units (OTUs) at
97% sequence identity, which allowed us to track changes in major
intra-host HCV variants over time.
In all LT subjects analyzed, 1–3 major variants dominated the
viral populations. Two major patterns were evident (Figure 3). In 9
subjects, the major variants that established re-infection post-LT
were identical or closely related to the dominant variants pre-LT
(Figure 3A). For the remaining 3 subjects, 1–2 minor variants pre-
LT became dominant post-LT (Figure 3B; data for all subjects are
shown in Supporting Information S1). In many subjects, the
overall genetic diversity immediately post-LT was low compared
to pre-LT (Shannon Index; Figure 3A and Supporting Informa-
tion S1). Despite the restricted diversity post-LT, all major variants
post-LT share a common ancestor with pre-LT lineages, and no
major clades were extinguished following LT.
We next asked whether the frequency and stability of variants
associated with NS3 resistance were influenced by the temporal
changes in intra-host HCV variants. In most subjects, the
abundance of RAVs was variable over time (Figure 2B). Notably,
Q80K was a common variant, detected in 28 of 47 samples.
Variants at positions V36, T54 and V55 were detected in 13% of
the samples, whereas substitutions at positions 155, 156 and 168
were uncommon (only 6.4% of the samples). With the exception of
Q80K, variants associated with NS3 resistance were minor
variants in nearly all cases.
Linkage mapping of drug resistance mutations
Linkage of mutations at V36 or T54 with R155 or A156 is
commonly selected in patients failing PI monotherapy and is
known to confer intermediate to high-level PI resistance [17,29].
Thus, it was of great interest to develop novel sensitive approaches
for mutational linkage analysis in vivo. Current sequencing
approaches suffer from several limitations. Population sequencing
cannot conclusively demonstrate linkage between different substi-
tutions on the same viral genome. Determining linkage of genetic
variants at low frequencies using the clonal sequencing approach
could be labor-intensive. For our pyrosequencing datasets, the
forward and reverse pyrosequencing reads (after trimming barcode
and primer sequences) did not have sufficient overlaps to allow
reconstruction of haplotypes for linkage analysis. Because the
Illumina paired-end sequencing technology can read both the
forward and reverse strands of each amplicon to provide long
range sequencing information during one paired-end read, we
asked whether the paired-end approach was suitable for long-
range linkage analysis in HCV.
The Illumina platform uses dye-terminated primer extension to
sequence DNA. The algorithm for base calling relies on
Table 1. Cont.






S 74 Male Caucasian 1b N/A 523,530 N/A




Time points indicate the number of days relative to the time of liver transplantation (number of days prior to liver transplant are indicated by a minus sign). For non-
transplant patients with chronic HCV, time points and immunosuppression regimen are not applicable (N/A). N/D: not determined.
doi:10.1371/journal.pone.0069698.t001
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fluorescent intensities from the first several nucleotides incorpo-
rated to normalize the fluorescent signals for subsequent nucleo-
tide extension. Thus, we first engineered barcodes that varied
between 4 and 8 nucleotides in length to reduce the likelihood that
adjacent clusters on the Illumina solid support would be scored as
one amplicon during sequencing. Next, we chose barcode
sequences to ensure that at least three different nucleotides were
represented. Lastly, we modified procedure for library preparation
to accommodate the standard paired-end sequencing protocol on
the Illumina platform (Figure 1).
We first introduced double mutations (T54A/R155K) using a
plasmid containing the wild-type H77C sequence and confirmed
the mutations by Sanger sequencing. Next, we synthesized their
transcripts in vitro, then reverse-transcribed and paired-end
sequenced the RT-PCR products. The sequencing data confirmed
that amino acid substitutions at position T54 and R155 for the
Figure 2. Frequency of NS3 resistance-associated variants (RAVs) in (A) chronic HCV and (B) longitudinal liver transplant recipients
as determined by Roche/454 pyrosequencing. The proportion of pyrosequencing reads that harbored authentic RAVs is indicated by the
intensity of magenta shown in the heatmap (p#0.05, chi-square test). RAVs detected in pyrosequence reads that were not significantly enriched
compared to background technical error rates are shown in grey (p.0.05, chi-square test). The background error rate was determined using in vitro
control transcripts of known sequence that were amplified and sequenced in parallel with the RNA extracted from HCV subjects. Each column is a
different sample, and each row represents a different RAV detected by pyrosequencing. Asterisks denote RAVs detected by direct Sanger sequencing.
In (A), each column is a different subject (14 genotype 1a and 6 genotype 1b), and in (B), longitudinal samples within each subject (as indicated by
the subject code at the bottom) are ordered from left to right, and phylogenetic analysis demonstrates that temporally associated samples are more
closely related within subjects than samples between subjects.
doi:10.1371/journal.pone.0069698.g002
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Figure 3. Dynamics of major NS3 variants in liver transplant recipients. Forward pyrosequence reads (,337 nt, corresponding to
coordinates 3342 to 3674 on the H77 genome, accession NC_004102) were clustered into operational taxonomic units (OTUs) at 97% sequence
identity. The relative abundance of each major variant is shown by the black shading, where the extent of the black region from left to right within
the gray bar indicates the proportion in the total viral population. The black double-headed arrow denotes the time of liver transplantation, and the
number of days before and after liver transplantation are indicated at the bottom. Trees were generated using UPGMA. Shannon diversity values
based on NS3 pyrosequence reads represent changes in NS3 diversity over time (Top panels). ALT: alanine aminotransferase. (A) The major variant
that established re-infection post-LT was identical or closely related to the dominant variant pre-LT (B) Two minor variants pre-LT became dominant
quasispecies post-LT.
doi:10.1371/journal.pone.0069698.g003
Table 2. Mutation linkage analyzed by Illumina paired-end sequencing.
V36 T54 V55 R155 A156 D168 I170 V36/R155 V36/A156 T54/R155 T54/A156
Control
WT 0.1 0.1 0.17 0.025 0.07 0.07 0.04 0 0 0.0007 0.00035
T54A 0.02 96.2 0.003 0.0003 0.42 0.0015 0.0005 0.00019 0.01 0.034 1.56
T54A+R155K 0.0005 0.3 0.0005 0.1 0.0001 0 0 0.128 0 99.6 0.05
Clinical Samples
E-1 0.29 0.3 0.34 0.09 0.11 0.16 0.27 0 0 0 0
G-4 0.19 0.15 0.29 0.03 0.09 0.06 0.14 0 0 0.001 0
I 0.19 0.22 0.29 0.05 0.094 0.17 0.16 0 0.0027 0.003 0.0003
J 0.001 0.004 0.98 0.0003 0 0 0.0003 0.0003 0.0003 0.0007 0.0003
Q-1 0.15 0.21 0.67 0.019 0.07 0.13 0.14 0 0 0 0.0009
Each row corresponds to an individual sample (control transcripts or clinical samples).
Each column corresponds to single or double mutant variants associated with PI resistance (WT codons are listed), and their mutation frequency (defined as non-WT) is
shown (%). Technical error rate was determined as 0.2% based on the WT control data.
doi:10.1371/journal.pone.0069698.t002
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T54A/R155K double mutant were linked in .99.6% of the
paired-end reads (Table 2, T54A+R155K). Based on the WT
data, the background technical error rate was determined to be
,0.2% (Table 2, WT; 321,3036202,093 reads per sample). Next,
we constructed four mock communities of in vitro RNA transcripts
to determine whether the mutation linkage in T54A+R155K
could be detected at low frequencies (Table 3). As shown in
Population 2, double mutant variants in as low as 0.5% of the total
RNA pool could be detected. The low prevalence and low
abundance of naturally occurring R155 and/or A156 mutations
precluded detailed analysis of low frequency linkage for most of
the samples in our cohort. Nevertheless, we chose 5 clinical
samples (Table 2, Clinical Samples) in which the R155 and/or
A156 mutations were detected at low frequencies by pyrosequenc-
ing (although not statistically enriched over the background error
rate) for linkage analysis. Double mutant variants associated with
high-level PI resistance were not detected in any of the five clinical
samples (i.e. all were below the background error rate). Overall,
mutation frequencies were in good agreement between the
Roche/454 and Illumina data sets (Supporting Information S1).
Discussion
This study presents an in-depth analysis of NS3 quasispecies
and resistance-associated variants (RAVs) in chronic HCV
infection and liver transplantation. With NS3/4A protease
inhibitors now in the clinic, there is a great deal of enthusiasm
for HCV therapeutics. While peginterferon-ribavirin still remains
the backbone of antiviral therapy, an interferon-free regimen with
combination DAAs will likely become a reality [9] and drug
resistance may be an important consideration in the foreseeable
future. Here, we used Roche/454 pyrosequencing to determine
abundance and Illumina paired-end sequencing to quantify
mutation linkage of naturally occurring RAVs in chronic HCV.
In addition, we describe temporal changes in viral populations
during liver transplantation.
Naturally occurring drug resistance mutations preexist in
treatment-naı̈ve individuals [12]. A recent survey using population
sequencing suggests that the prevalence of NS3 RAVs is low in
genotype 1 DAA-naı̈ve patients [30]. However, since population
sequencing reports only the most predominant nucleotides in a
given sequence, the conventional method is not sensitive in
detecting minor variants present in less than 20% of the viral
population. Thus, the baseline prevalence of NS3 RAVs may be
higher if more sensitive techniques were used. Importantly, linkage
of minor variants from different parts of the genome is not possible
with population sequencing. In our cohort, conventional sequenc-
ing failed to detect minority variants in most subjects, while some
RAVs could be identified using more extensive clonal sequencing.
Our data demonstrate that naturally occurring RAVs are common
in transplant recipients both before and after LT. The prevalence
of Q80K/R polymorphism was particularly high, approaching
70–80% in our cohort (78% of genotype 1a and 50% of genotype
1b samples), which were significantly higher than previously
reported [30,31]. Interestingly, Q80K was frequently a dominant
variant in the viral swarm, but substitutions at V36, T54 and V55
were generally minor variants (,5% of pyrosequence reads).
Variants conferring high-level drug resistance (i.e. substitutions at
155, 156 and 168) were rare; no dominant mutation at these
positions was detected in our dataset. These data are consistent
with the recent data obtained using population sequencing
methods [30], in which HCV variants with lower-level resistance
were detectable but higher-level resistant variants were not
observed. Our data is also consistent with the hypothesis that
the abundance of RAVs may be a function of viral fitness in
quasispecies populations. In a recent study, RAVs were detected in
most subjects who failed to achieve SVR following combination
therapy that includes protease inhibitor. Following the withdrawal
of DAAs, different RAVs were gradually replaced by wild-type
virus at different rates over time, presumably due to the differential
fitness of the specific resistant variants [32,33].
A significant advance of this study is the novel application of the
Illumina paired-end sequencing technology to mutation linkage
analysis. To our knowledge, this is the first report of mapping
linkage of viral drug resistance using this approach. Using in vitro
control transcripts, we demonstrate that linked variants constitut-
ing as low as 0.5% of the overall RNA population could be
detected and their linkage confirmed. The differences between the
predicted and measured frequencies in our mock populations
could be explained by differential PCR amplifications leading to
skewing of allelic frequencies. In HIV, it has been shown that PCR
amplification could skew the abundance measurement by 2 to 15
fold, and in some cases the effects can be severe (up to 100-fold)
[34]. Going forward, it would be of interest to improve upon our
current methods by combining strategies such as PrimerID [34]
with the sensitive Illumina approach employed in this study. The
combined approach could control for allelic skewing as well as
template resampling and sequencing errors, thereby allowing for
more accurate quantification of mutation linkage. In this study,
double PI mutants were not detected in our PI-naı̈ve cohort. This
finding was not surprising as double PI mutants likely suffer from
poor fitness compared to WT and the frequency of resistance
variants is generally determined by its replicative fitness. Since
mutations at V36 or T54 linked to R155 or A156 confer high-level
resistance to NS3/4A inhibitors, the paired-end sequencing
approach should be suitable for sensitive NS3 linkage analysis
during pretreatment and early DAA therapy. More broadly, the
Table 3. Illumina paired-end sequencing identifies low frequency T54A+R155K double mutant in mock RNA populations.
Population 1 Population 2 Population 3 Population 4
Expected Observed Expected Observed Expected Observed Expected Observed
WT 92.6 92.77 87.1 91.16 98.6 96.37 35.2 48.6
T54A 1.3 6.0 12.3 8.28 1.2 3.5 44.5 42.76
T54A/R155K 6.0 1.08 0.56 0.45 0.058 0.029 20.4 8.07
RNA transcripts were synthesized from WT, T54A, or T54A+R155K plasmid in vitro. Each mock population of RNA transcripts was constructed according to the
proportions indicated in the ‘‘Expected’’ column. The proportion of paired-end reads that harbored T54A single mutant, T54A/R155K double mutant, or WT are shown in
the ‘‘observed’’ column (%). While the double mutant at a level below 0.1% was detected (Population 3), it was below our experimentally determined threshold for
background error rate of ,0.2% (see Table 2).
doi:10.1371/journal.pone.0069698.t003
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paired-end strategy could be applied to other drug-targeted loci in
HCV as well as other viruses such as HIV and HBV.
A major challenge in studies of viral quasispecies and RAVs
using next-generation sequencing technology is the potential
erroneous drug resistance calls due to technical artifacts. These
artifacts could arise during sample preparation, including reverse
transcription and PCR, as well as from the Roche/454 or Illumina
sequence determination step. We took several quality control
measures to estimate and correct for the background technical
error rates. First, we quantified RNA templates by quantitative
RT-PCR to minimize resampling of low viral load RNA templates
(our one-step RT-PCR procedure did not permit direct measure-
ment of cDNA copy numbers), and we observed no correlations
between input RNA template and quasispecies diversity to suggest
template resampling (Supporting Information S1). Secondly, we
used in vitro transcribed RNA rather than plasmid DNA as controls
to correct for errors introduced during the RT step. Although
errors generated during in vitro transcription could artificially
inflate the measured error rate, RNA polymerase error rate is
generally lower compared to that of RT which has been previously
shown to be a negligible source of errors compared to
pyrosequencing errors [19]. Next, through a combination of
global and pairwise sequence alignments followed by manual
inspection of reads containing codon-changing nucleotide substi-
tutions, we conservatively called authentic RAVs only if the
detected variant was statistically enriched over position-specific
errors determined for the control RNA transcript. The technical
error rates determined in our control experiments were consistent
with error rates published previously [21][35,36]. Thus, while our
454 dataset revealed a large number of RAVs (i.e. grey and
magenta boxes in Figures 2 and 3), only ,30% of the detected
RAVs were considered authentic by our stringent criteria.
Longitudinal analysis of LT recipients allowed us to track
temporal changes of intra-host viral variants. In most subjects, the
predominant viral variant remained relatively stable over several
years, whereas in others, a minor variant pre-LT became a major
variant post-LT. In all subjects, the major viral variants post-LT
shared a common ancestor with viral lineages pre-LT. These
results are consistent with the recent clonal sequencing data based
on hypervariable envelope sequences in the same transplant
cohort [37], but differ from an earlier study using clonal analysis,
where viral genetic bottleneck was observed for the short period
immediately following liver transplantation (,1 months) [38]. It
would be of great interest to confirm the stability of HCV
populations and RAVs in other LT cohorts, as well as other
longitudinal cohorts such as treatment-naı̈ve chronic HCV and
HIV-HCV co-infection, as this will have a direct impact on the
selection of effective DAA agents for combination antiviral
therapy.
Intense efforts are presently focused on the development of
therapeutics for HCV. Our results indicate that RAVs pre-exist in
the viral swarm at low levels not readily detectable by conventional
sequencing in most patients. This study also demonstrates that
mutation linkage at low levels could be detected using our
modified Illumina paired-end sequencing approach. Although
recent data suggest that the presence of DAA-resistant variants
in treatment-naı̈ve patients at baseline receiving IFN and protease
inhibitor- containing combination therapy does not impact
sustained viral response rate, the effect of specific resistant variant
frequency on the response to IFN-free DAA regimens remains
clear. As we move toward an era of interferon-free oral antiviral
therapy, the determination of pre-existing RAVs prior to therapy
may be important as nearly 100% of new livers are re-infected by
viruses present in the bloodstream, old liver or peripheral blood
mononuclear cells [1,39,40]. The full clinical significance of these
pre-existing RAVs remains to be defined in prospective studies,
but is important as interferon-based therapy is currently the only
approved treatment for post-LT HCV re-infection. The methods
described here should be widely applicable to detailed studies of
pre-existing and low-level drug resistance, mutation linkage, and
viral dynamics in patients undergoing direct acting antiviral
therapies.
Supporting Information
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mation file containing supplementary methods, tables
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RNA isolation, primer design/RT-PCR amplification, RNA
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ing. Supplementary tables include information on primers, read
filtering, variant frequencies, and alpha diversity. The supplemen-
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